Akari Therapeutics Hires Experienced Life Sciences Executive (12 words)

Biotechnology company Akari Therapeutics, Plc has announced the appointment of Samir R. Patel, M.D. to its Board of Directors. Dr. Patel brings extensive experience in the life sciences industry, having co-founded multiple successful startup companies and holding various roles in medical affairs. His appointment comes at a crucial time for Akari as it develops advanced therapies for autoimmune and inflammatory diseases.

Dr. Patel currently serves as the founder and principal of PranaBio Investments, LLC, where he provides consulting, strategic advisory, and investment services for small cap biotechnology companies. He also works as a consultant to GE Global Research, focusing on biomanufacturing and biotechnology. With over 20 years of experience in the field, Dr. Patel holds multiple patents and has been involved in numerous clinical research studies.

Akari Therapeutics, Plc specializes in developing advanced therapies for autoimmune and inflammatory diseases. It is currently focused on its lead asset, investigational nomacopan, which is a bispecific recombinant inhibitor. The company’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has received various designations from regulatory authorities, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations. In addition to pediatric HSCT-TMA, Akari is also researching nomacopan for adult HSCT-TMA and long-acting PAS-nomacopan in geographic atrophy (GA).

Help improve our content system

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

Share this story:

Transplant News
Transplant News

Transplant News brings you the news and content that matters to the transplant community. From patient stories, to the latest in transplant innovation, Transplant News is your window into the world of transplantation.